- Isis Pharmaceuticals has begun Phase I trials with ISIS 5320 forthe treatment of HIV infection. The compound works via a novel mechanism - it is negatively charged and binds to a particular region of the gp120 protein, which prevents virus-to-cell and cell-to-cell transmission, says the company. It has shown in vitro activity against a range of HIV-1 and HIV-2 strains, with no resistance noted as yet.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze